Find Galantamine Benzoate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Gln-1062, 224169-27-1, Galantamine benzoate, Xoi2q0zf7g, 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, benzoate (ester), (4as,6r,8as)-, Benzgalantamine
Molecular Formula
C24H25NO4
Molecular Weight
391.5  g/mol
InChI Key
JKVNJTYHRABHIY-WXVUKLJWSA-N
FDA UNII
XOI2Q0ZF7G

Galantamine Benzoate
1 2D Structure

Galantamine Benzoate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
[(1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-yl] benzoate
2.1.2 InChI
InChI=1S/C24H25NO4/c1-25-13-12-24-11-10-18(28-23(26)16-6-4-3-5-7-16)14-20(24)29-22-19(27-2)9-8-17(15-25)21(22)24/h3-11,18,20H,12-15H2,1-2H3/t18-,20-,24-/m0/s1
2.1.3 InChI Key
JKVNJTYHRABHIY-WXVUKLJWSA-N
2.1.4 Canonical SMILES
CN1CCC23C=CC(CC2OC4=C(C=CC(=C34)C1)OC)OC(=O)C5=CC=CC=C5
2.1.5 Isomeric SMILES
CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)OC(=O)C5=CC=CC=C5
2.2 Other Identifiers
2.2.1 UNII
XOI2Q0ZF7G
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Gln-1062

2.3.2 Depositor-Supplied Synonyms

1. Gln-1062

2. 224169-27-1

3. Galantamine Benzoate

4. Xoi2q0zf7g

5. 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, Benzoate (ester), (4as,6r,8as)-

6. Benzgalantamine

7. Unii-xoi2q0zf7g

8. Benzgalantamine [inn]

9. Schembl16885442

10. [(1s,12s,14r)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-yl] Benzoate

11. Gln 1062

12. Cs-6749

13. Hy-101710

2.4 Create Date
2009-10-26
3 Chemical and Physical Properties
Molecular Weight 391.5 g/mol
Molecular Formula C24H25NO4
XLogP34.1
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count5
Rotatable Bond Count4
Exact Mass391.17835828 g/mol
Monoisotopic Mass391.17835828 g/mol
Topological Polar Surface Area48 Ų
Heavy Atom Count29
Formal Charge0
Complexity645
Isotope Atom Count0
Defined Atom Stereocenter Count3
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

API SUPPLIERS

read-more
read-more

01

GLP Bio

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

GLP Bio

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

02

FandaChem

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

FandaChem

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

03

Axon Medchem

Netherlands

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

Axon Medchem

Netherlands

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

04

Haoyuan Chemexpress Co.Ltd

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

Axon Medchem

Netherlands
AACR Annual meeting
Not Confirmed
arrow

Axon Medchem

Netherlands
arrow
AACR Annual meeting
Not Confirmed

Galantamine Benzoate

About the Company : ors, ligands and libraries About Axon Medchem Axon Medchem is a leading European service platform for medicinal chemistry, spinned-off from Axon Biochemicals BV. Together...

ors, ligands and libraries About Axon Medchem Axon Medchem is a leading European service platform for medicinal chemistry, spinned-off from Axon Biochemicals BV. Together with Axon Biochemicals BV, it conducts business operations as a contract research organization (CRO) in medicinal chemistry. Subsequent to the spin-off in 2006, Axon Medchem has developed as a prime source of high-value life science products, providing Axon Ligands™ for pharmaceutical research as world-wide recognized drug standards.
blank

02

FandaChem

China
AACR Annual meeting
Not Confirmed
arrow

FandaChem

China
arrow
AACR Annual meeting
Not Confirmed

Galantamine Benzoate

About the Company : FandaChem, headquartered in Hangzhou, China, is a reputable supplier and exporter of chemicals with a focus on delivering high-quality products. Our expertise lies in exporting a w...

FandaChem, headquartered in Hangzhou, China, is a reputable supplier and exporter of chemicals with a focus on delivering high-quality products. Our expertise lies in exporting a wide range of superior chemicals, specializing in areas such as agrochemicals, flavors, fragrances, pharmaceuticals, intermediates, paints, resins, plastics, surfactants, polymers, cosmetics, and more. Dedicated to being your dependable partner in China, FandaChem is devoted to offering top-notch products, competitive prices, and excellent service to meet the needs of our customers.
blank

03

GLP Bio

U.S.A
AACR Annual meeting
Not Confirmed
arrow

GLP Bio

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Galantamine Benzoate

About the Company : Glpbio Technology Inc is a leading supplier specializing in small molecule inhibitors, activators, compound libraries, peptides, and laboratory reagents. With a vast inventory of o...

Glpbio Technology Inc is a leading supplier specializing in small molecule inhibitors, activators, compound libraries, peptides, and laboratory reagents. With a vast inventory of over 30,000 products spanning more than 20 research fields including cancer, immunology, neurosciences, apoptosis, and epigenetics, Glpbio offers a comprehensive range of solutions for scientific research. Our commitment to quality and innovation ensures that researchers worldwide have access to high-quality tools and compounds essential for advancing discoveries in biomedicine and beyond.
blank

04

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Galantamine Benzoate

About the Company : Haoyuan Chemexpress Co., Ltd., located in Shanghai Zhangjiang Biomedical Base, is a high-tech company specializing in customized chemical synthesis and R&D of pharmaceutical interm...

Haoyuan Chemexpress Co., Ltd., located in Shanghai Zhangjiang Biomedical Base, is a high-tech company specializing in customized chemical synthesis and R&D of pharmaceutical intermediates and new drugs. The company is mainly engaged in customized synthesis of complex small molecule frameworks and pharmaceutical intermediates, and independent R&D of innovative new drugs; and provides services of production technology improvement and consigned new drug development for pharmaceutical enterprises. Haoyuan Chemexpress is committed to researching and developing APIs and pharmaceutical intermediates with high synthesis technology barriers and difficulties and high added value, and also focuses on the synthesis of chiral compounds.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Zunveyl (benzgalantamine gluconate) is a an acetylcholinesterase inhibitor, small molecule drug being evaluated for the treatment of mild to moderate alzheimer’s disease.


Lead Product(s): Galantamine Benzoate

Therapeutic Area: Neurology Brand Name: Zunveyl

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 18, 2025

blank

01

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : Zunveyl (benzgalantamine gluconate) is a an acetylcholinesterase inhibitor, small molecule drug being evaluated for the treatment of mild to moderate alzheimer’s disease.

Product Name : Zunveyl

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

March 18, 2025

blank

Details:

Under the licensing agreement, CMS will hold the exclusive right for the development, manufacturing, and commercialization of Zunveyl (benzgalantamine) for the treatment of Alzheimer’s disease.


Lead Product(s): Galantamine Benzoate

Therapeutic Area: Neurology Brand Name: Zunveyl

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: China Medical System Holdings Limited

Deal Size: $44.0 million Upfront Cash: $6.0 million

Deal Type: Licensing Agreement January 08, 2025

blank

02

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Lead Product(s) : Galantamine Benzoate

Therapeutic Area : Neurology

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : China Medical System Holdings Limited

Deal Size : $44.0 million

Deal Type : Licensing Agreement

Details : Under the licensing agreement, CMS will hold the exclusive right for the development, manufacturing, and commercialization of Zunveyl (benzgalantamine) for the treatment of Alzheimer’s disease.

Product Name : Zunveyl

Product Type : Other Small Molecule

Upfront Cash : $6.0 million

January 08, 2025

blank

Details:

The Company intends to use the proceeds towards the commercialization and launch of Zunveyl (benzgalantamine) for the treatment of mild-to-moderate Alzheimer’s Disease.


Lead Product(s): Galantamine Benzoate

Therapeutic Area: Neurology Brand Name: Zunveyl

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Titan Partners Group LLC

Deal Size: $50.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering December 11, 2024

blank

03

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : The Company intends to use the proceeds towards the commercialization and launch of Zunveyl (benzgalantamine) for the treatment of mild-to-moderate Alzheimer’s Disease.

Product Name : Zunveyl

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

December 11, 2024

blank

Details:

Zunveyl (benzgalantamine) is a new generation acetylcholinesterase inhibitor. It is being evaluated for treatment of repetitive mild traumatic brain injury.


Lead Product(s): Galantamine Benzoate

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Zunveyl

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 11, 2024

blank

04

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : Zunveyl (benzgalantamine) is a new generation acetylcholinesterase inhibitor. It is being evaluated for treatment of repetitive mild traumatic brain injury.

Product Name : Zunveyl

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

December 11, 2024

blank

Details:

The proceeds from the financing will be utilized to continue commercialization work for the Company’s recently approved Zunveyl (benzgalantamine), indicated for the treatment of Alzheimer's disease.


Lead Product(s): Galantamine Benzoate

Therapeutic Area: Neurology Brand Name: Zunveyl

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: The Benchmark Company

Deal Size: $4.5 million Upfront Cash: Undisclosed

Deal Type: Financing September 24, 2024

blank

05

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : The proceeds from the financing will be utilized to continue commercialization work for the Company’s recently approved Zunveyl (benzgalantamine), indicated for the treatment of Alzheimer's disease.

Product Name : Zunveyl

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

September 24, 2024

blank

Details:

ZUNVEYL, a prodrug of AD treatment galantamine and an acetylcholinesterase inhibitor (AChEI), is postulated to exert its therapeutic effect by preventing the breakdown of acetylcholine.


Lead Product(s): Galantamine Benzoate

Therapeutic Area: Neurology Brand Name: Zunveyl

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 29, 2024

blank

06

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : ZUNVEYL, a prodrug of AD treatment galantamine and an acetylcholinesterase inhibitor (AChEI), is postulated to exert its therapeutic effect by preventing the breakdown of acetylcholine.

Product Name : Zunveyl

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

July 29, 2024

blank

Details:

The company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.


Lead Product(s): Galantamine Benzoate

Therapeutic Area: Neurology Brand Name: Alpha-1062

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Undisclosed

Deal Size: $6.5 million Upfront Cash: Undisclosed

Deal Type: Public Offering December 22, 2023

blank

07

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : The company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.

Product Name : Alpha-1062

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

December 22, 2023

blank

Details:

The Company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.


Lead Product(s): Galantamine Benzoate

Therapeutic Area: Neurology Brand Name: Alpha-1062

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Undisclosed

Deal Size: $97.8 million Upfront Cash: Undisclosed

Deal Type: Private Placement October 16, 2023

blank

08

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : The Company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.

Product Name : Alpha-1062

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

October 16, 2023

blank

Details:

ALPHA-1062, a proprietary, patented, delayed release oral tablet formulation in development for the treatment of mild-to-moderate Alzheimer’s Disease.


Lead Product(s): Galantamine Benzoate

Therapeutic Area: Neurology Brand Name: Alpha-1062

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 27, 2023

blank

09

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : ALPHA-1062, a proprietary, patented, delayed release oral tablet formulation in development for the treatment of mild-to-moderate Alzheimer’s Disease.

Product Name : Alpha-1062

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

September 27, 2023

blank

Details:

The Company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.


Lead Product(s): Galantamine Benzoate

Therapeutic Area: Neurology Brand Name: Alpha-1062

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Undisclosed

Deal Size: $1.3 million Upfront Cash: Undisclosed

Deal Type: Private Placement August 31, 2023

blank

10

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : The Company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.

Product Name : Alpha-1062

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

August 31, 2023

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Galantamine Benzoate

Brand Name : Zunveyl

Dosage Form :

Dosage Strength : 5MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Dossiers

read-more
read-more

01

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Galantamine Benzoate

Brand Name : Zunveyl

Dosage Form :

Dosage Strength : 5MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country :

blank

01

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Galantamine Benzoate

Dosage :

Dosage Strength : 5MG

Brand Name : Zunveyl

Approval Date :

Application Number :

Registration Country :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

STOCK RECAP #PipelineProspector

read-more
read-more
Pipeline Prospector July 2024: Indices continue to climb; Lilly buys Morphic for US$ 3.2 bn, Kisunla bags FDA nod
The biotechnology sector ended in the green for the third month in a row in July, significantly outperforming the broader market. The Nasdaq Biotechnology Index (NBI) climbed by a robust 6.6 percent, closing at 4,843.6, up from a close of 4,545.28 in June. Similarly, the SPDR S&P Biotech ETF (XBI) index surged by 6.8 percent, reaching 99.06, up from June’s closing of 92.71. The S&P Biotechnology Select Industry Index (SPSIBI) followed suit, jumping 6.8 percent to 7,716.95 compared to a 4.25 percent rise in June, when it closed at 7,225.07.The month saw a few significant deals. Eli Lilly announced the acquisition of Massachusetts-based Morphic Holding for approximately US$ 3.2 billion in cash, bolstering its presence in the US$ 26.65 billion inflammatory bowel disease (IBD) market. Lilly also signed a strategic deal with radiopharmaceutical company Radionetics Oncology for US$ 140 million, with an option to purchase the entire company for US$ 1 billion. As the month drew to a close, Boehringer Ingelheim said it is acquiring Nerio Therapeutics for up to US$ 1.3 billion, in order to expand its immuno-oncology portfolio. Access the Pipeline Prospector Dashboard for July 2024 Newsmakers (Free Excel)Lilly’s donanemab finally gets approved; Dupixent okayed as add-on therapy for COPDWith the Alzheimer's Association International Conference (AAIC) taking place in Philadelphia (in the US), the spotlight was firmly on Alzheimer’s disease. In the last week of July, the US Food and Drug Administration (FDA) approved Alpha Cognition’s Zunveyl (benzgalantamine) to treat mild-to-moderate Alzheimer’s disease. In early July, and weeks prior to the conference, the FDA had granted a long-awaited approval to Eli Lilly’s donanemab, to be marketed as Kisunla, for the treatment of early symptomatic Alzheimer’s disease.In other approvals, European regulators became the first in the world to approve Sanofi and Regeneron’s Dupixent as an add-on therapy for chronic obstructive pulmonary disease (COPD) patients with high levels of certain white blood cells.In May, FDA had extended its target action date of its priority review of Dupixent as an add-on maintenance treatment for COPD by three months. The revised target action date is now September 27, 2024. Access the Pipeline Prospector Dashboard for July 2024 Newsmakers (Free Excel)Merck’s RSV jab shows efficacy in infants; GSK’s Dovato measures up to Gilead’s BiktarvyMerck said its monoclonal antibody jab to protect infants against RSV-related infections has met the main goals of a mid-to-late-stage trial. Clesrovimab reduced medically attended lower respiratory infections caused by RSV through day 150. Merck plans to submit the data to global regulators. Currently, Sanofi and Astra’s Beyfortus is approved by the FDA to prevent RSV in children up to 24 months.In the largest study of its kind, GSK’s HIV drug Dovato was found to be non-inferior to Gilead Sciences’ Biktarvy, which is seen as the benchmark for HIV treatment. Significantly, Dovato did so with lesser weight gain in a 48-week head-to-head study of virologically suppressed HIV-1 patients. Both Dovato and Biktarvy are single pill treatments for HIV given once a day. Biktarvy raked in US$ 11.9 billion in 2023.Pfizer’s gene therapy for hemophilia A, giroctocogene fitelparvovec, showed promising results in a late-stage trial by significantly reducing the number of annual bleeding episodes. This brings Pfizer closer to securing FDA approval, competing with BioMarin’s Roctavian. Pfizer also said it is moving ahead to mid-stage trials with a once-daily version of its glucagon-like peptide 1 (GLP-1) drug danuglipron for weight loss. In December, Pfizer had discontinued a twice-daily version of danuglipron on account of side effects. Pfizer’s stock also benefited from its healthy second quarter (Q2) results.Swiss drugmaker Roche is reintroducing Susvimo in the US after voluntarily recalling it in October 2022. The implant used to treat patients with neovascular age-related macular degeneration (wet AMD) requires a one-time surgery to be inserted into the eye.Roche also revealed that a second drug candidate from its up to US$ 3.1 billion buyout of Carmot Therapeutics — an obesity drug —  has delivered promising results in an early-stage trial. This once-daily weight-loss pill CT-996 reduced on average 6.1 percent of participants’ starting weight after four weeks. CT-996 works in a similar manner as other blockbuster weight loss drugs, such as Wegovy and Zepbound. Access the Pipeline Prospector Dashboard for July 2024 Newsmakers (Free Excel)Biogen-Sage’s essential tremor drug rejected; Novo’s weekly insulin hit with FDA’s CRL Several drugmakers faced setbacks last month. Novo Nordisk received a complete response letter (CRL) from the FDA, declining approval for its weekly insulin Awiqli. The agency requested additional information related to the manufacturing process, as well as on the type 1 diabetes indication. In May, an FDA panel had voted seven to four against the benefits of Awiqli outweighing its risks. Sage and Biogen’s partnership experienced another setback after the failure of their drug SAGE-324 in a phase 2 trial for essential tremor, a disorder that causes uncontrollable shaking of hands, arms and other parts of the body. This follows the previous failure of Zurzuvae to secure an FDA approval for clinical depression.Meanwhile, Eisai and Biogen’s Alzheimer’s drug Leqembi, faced a setback in Europe when the EU drugs regulator rejected its approval. The European Medicines Agency said the drug’s meager benefit on slowing cognitive decline in early Alzheimer’s did not outweigh the risk it brings of serious brain swelling. Leqembi is approved in the US market, where it has a new competitor — Lilly’s Kisunla.Also, BMS walked away from its rights to the ADC farletuzumab ecteribulin after having paid Japanese drugmaker Eisai US$ 650 million. As part of its portfolio reprioritization, BMS decided to end the co-development agreement. Access the Pipeline Prospector Dashboard for July 2024 Newsmakers (Free Excel) Our viewAs July drew to a close, several pharma majors announced their second quarter (Q2) earnings, including Pfizer, Merck, AbbVie and, AstraZeneca. Most of these drugmakers ended up beating Wall Street expectations. For instance, Pfizer saw revenue growth in Q2 after shrinking for five quarters. It posted revenues of US$ 13.3 billion in the second quarter of 2024, compared to US$ 13 billion in the corresponding quarter last year. It has subsequently raised its 2024 guidance by US$ 1 billion. This means it’s not just the indices and share prices, but even the brass tacks — the top line and the bottomline of drugmakers — are looking up. And that may bring more cheer to the markets in August. Access the Pipeline Prospector Dashboard for July 2024 Newsmakers (Free Excel) 

Impressions: 2440

https://www.pharmacompass.com/pipeline-prospector-blog/indices-continue-to-climb-lilly-buys-morphic-for-us-3-2-bn-its-alzheimer-s-drug-finally-bags-fda-nod

#PharmaFlow by PHARMACOMPASS
01 Aug 2024

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20250319665873/en/Alpha-Cognition-Announces-the-Commercial-Launch-of-ZUNVEYL-Benzgalantamine-for-the-Treatment-of-Mild-to-Moderate-Alzheimers-Disease

BUSINESSWIRE
18 Mar 2025

https://www.businesswire.com/news/home/20250212688224/en

BUSINESSWIRE
12 Feb 2025

https://www.businesswire.com/news/home/20250108752271/en

BUSINESSWIRE
08 Jan 2025

ABOUT THIS PAGE

Looking for 224169-27-1 / Galantamine Benzoate API manufacturers, exporters & distributors?

Galantamine Benzoate manufacturers, exporters & distributors 1

45

PharmaCompass offers a list of Galantamine Benzoate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Galantamine Benzoate manufacturer or Galantamine Benzoate supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Galantamine Benzoate manufacturer or Galantamine Benzoate supplier.

PharmaCompass also assists you with knowing the Galantamine Benzoate API Price utilized in the formulation of products. Galantamine Benzoate API Price is not always fixed or binding as the Galantamine Benzoate Price is obtained through a variety of data sources. The Galantamine Benzoate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Galantamine Benzoate

Synonyms

Gln-1062, 224169-27-1, Xoi2q0zf7g, 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, benzoate (ester), (4as,6r,8as)-, Benzgalantamine, Unii-xoi2q0zf7g

Cas Number

224169-27-1

Unique Ingredient Identifier (UNII)

XOI2Q0ZF7G

Galantamine Benzoate Manufacturers

A Galantamine Benzoate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Galantamine Benzoate, including repackagers and relabelers. The FDA regulates Galantamine Benzoate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Galantamine Benzoate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Galantamine Benzoate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Galantamine Benzoate Suppliers

A Galantamine Benzoate supplier is an individual or a company that provides Galantamine Benzoate active pharmaceutical ingredient (API) or Galantamine Benzoate finished formulations upon request. The Galantamine Benzoate suppliers may include Galantamine Benzoate API manufacturers, exporters, distributors and traders.

click here to find a list of Galantamine Benzoate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Galantamine Benzoate GMP

Galantamine Benzoate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Galantamine Benzoate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Galantamine Benzoate GMP manufacturer or Galantamine Benzoate GMP API supplier for your needs.

Galantamine Benzoate CoA

A Galantamine Benzoate CoA (Certificate of Analysis) is a formal document that attests to Galantamine Benzoate's compliance with Galantamine Benzoate specifications and serves as a tool for batch-level quality control.

Galantamine Benzoate CoA mostly includes findings from lab analyses of a specific batch. For each Galantamine Benzoate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Galantamine Benzoate may be tested according to a variety of international standards, such as European Pharmacopoeia (Galantamine Benzoate EP), Galantamine Benzoate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Galantamine Benzoate USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty